Evotec’s Restructuring Plan Weighs on Shares Amid Divergent Business Performance

Evotec SE has announced a sweeping operational overhaul, sending its stock price lower as the market digested a sharply reduced profit outlook. The life sciences company’s new “Horizon” restructuring program will see it cut approximately one-sixth of its global workforce and significantly consolidate its site network. This decisive action comes in response to mounting pressure in its core business, despite a standout performance from its biologics division.

The company’s financial guidance for the current 2026 fiscal year underscores the near-term cost of this transition. Management now anticipates adjusted EBITDA to land between zero and 40 million euros. This forecast fell substantially below market expectations, with analysts having previously projected a figure exceeding 80 million euros. The announcement has extended a painful trend for shareholders; the stock has declined roughly 23% since the start of the year, with its price currently standing at 4.27 euros.

A Company Operating on Two Tracks

The rationale for the drastic “Horizon” measures lies in a pronounced split within Evotec’s operations. The firm’s traditional core business, focused on preclinical development, contracted by 13% in 2025 and slipped into an operating loss. In stark contrast, the Just Evotec Biologics unit flourished, reporting a revenue increase of around 40% to 259 million euros for the past year. This growth was propelled by significant milestones, including a recent agreement with Sandoz.

Should investors sell immediately? Or is it worth buying Evotec?

Faced with this dichotomy, CEO Christian Wojczewski is implementing a rigorous cost-cutting strategy. The plan involves eliminating up to 800 positions and closing four additional sites. The objective is to create a leaner, more efficient global footprint, ultimately reducing the company’s operational locations to just ten.

A Transition Year with Long-Term Ambitions

Company leadership has explicitly framed 2026 as a transitional period, noting that operational improvements in the core business are not expected before the second half of the year. The firm’s long-term strategy, however, remains ambitious. Leveraging the technological foundation of its continuous manufacturing platform in biologics, Evotec aims to shift its portfolio toward higher-margin contracts. The corporate goal is to achieve revenue surpassing the one-billion-euro mark by 2030.

Evotec has stated it will provide comprehensive details on its financial planning and the specific timeline for the Horizon initiative on April 8, 2026, when it releases its final annual results. The current environment, characterized by pharmaceutical companies scrutinizing research budgets more closely, continues to present significant challenges for the broader sector.